Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
British Dental Journal|April 10, 2021
Heroes or villains?Simon Fear
Swiss Medical Weekly|May 14, 2020
Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practiceRichard Cathomas, Julian Schardt, Miklos Pless, et al.
Gastroenterology|June 11, 2002
Diet and colorectal cancer: an investigation of the lectin/galactose hypothesisRichard C Evans, Simon Fear, Deborah Ashby, et al.
Pharmaceutical Medicine|December 8, 2021
Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European UnionHina Patel, Thanh G N Ton, Jessica Davies, et al.
The Journal of Urology|April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World PracticeAxel S Merseburger, Daniel Castellano, Thomas Powles, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2020
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinomaYohann Loriot, Cora N Sternberg, Daniel Castellano, et al.
European Urology Focus|November 10, 2020
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract CarcinomaJens Bedke, Axel S Merseburger, Yohann Loriot, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
Pageof 1